287952-67-4

Basic information

• Product Name: 4-[4-(TRIFLUOROMETHOXY)PHENOXY]PIPERIDINE
• Synonyms: Piperidine, 4-[4-(trifluoroMethoxy)phenoxy]-;4-[4-(TrifluoroMethoxy)phenoxy]piperidine HCl;Delamanid intermediate
• CAS NO: 287952-67-4
• Molecular Formula: C₁₂H₁₄F₃NO₂
• Molecular Weight: 261.25
• Mol File: 287952-67-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 71-73℃
• Boiling Point: 292.2°Cat760mmHg
• Flash Point: 130.5°C
• Appearance: /
• Density: 1.23g/cm³
• Vapor Pressure: 0.00151mmHg at 25°C
• Refractive Index: 1.473
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.65±0.10(Predicted)
• CAS DataBase Reference: 4-[4-(TRIFLUOROMETHOXY)PHENOXY]PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(TRIFLUOROMETHOXY)PHENOXY]PIPERIDINE(287952-67-4)
• EPA Substance Registry System: 4-[4-(TRIFLUOROMETHOXY)PHENOXY]PIPERIDINE(287952-67-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 287952-67-4(Hazardous Substances Data)

Usage

Uses

4-[4-(Trifluoromethoxy)phenoxy]piperidine is used in the preparation of 3,5-disubstituted isoxazolines as antituberculosis agents.

InChI:InChI=1/C12H14F3NO/c13-12(14,15)9-1-3-10(4-2-9)17-11-5-7-16-8-6-11/h1-4,11,16H,5-8H2

Upstream product

• 1501963-64-9 4-(4-(trifluoromethoxy)phenoxy)piperidine hydrochloride 
• 828-27-3 4-Trifluoromethoxyphenol 
• 65214-82-6 4-hydroxy-piperidine-1-carboxylic acid ethyl ester 
• 287952-21-0 4-[(4-trifluoromethoxy)phenyl]methoxypiperidine-1-formic acid tert-butyl ester 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 50824-05-0 4-trifluoromethoxybenzyl bromide 
• 1083099-54-0 4-(4-trifluoromethoxy-phenoxy)-pyridine 
• 1083099-51-7 1-ethoxycarbonyl-4-(4-trifluoromethoxy-phenoxy)-piperidine 
• 287952-66-3 tert-butyl 4-(4-(trifluoromethoxy)phenoxy)piperidin-1-carboxylate 

Downstream Products

• 308386-10-9 2-[4-(4-trifluoromethoxy-phenoxy)-piperidine-1-sulfonyl]-benzoic acid ethyl ester 
• 733751-05-8 (4-methanesulfonyl-phenyl)-{5-nitro-6-[4-(4-trifluoromethoxy-phenoxy)-piperidin-1-yl]-pyrimidin-4-yl}-amine 
• 681482-81-5 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine 
• 1083099-55-1 1-(4-benzyloxy-phenyl)-4-(4-trifluoromethoxy-phenoxy)-piperidine 
• 866109-93-5 4-(4-(4-trifluoromethoxy-phenoxy)piperidin-1-yl)phenol para-toluenesulfonic acid salt 
• 1346017-80-8 2-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)ethanol 
• 1346017-83-1 ethyl 3-(4-((4-trifluoromethoxy)phenoxy)piperidin-1-yl)propionate 
• 1346017-85-3 3-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)propionic acid 
• 1346017-93-3 3-(2-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)ethoxy)propionyl chloride 
• 1346017-94-4 ethyl 3-(2-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)ethoxy)propionate 
• 1346017-95-5 3-(2-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)ethoxy)propionic acid 
• 1346017-61-5 (S)-N-(6,7-dihydro-2-nitro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-3-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl) propanamide 
• 1346017-81-9 3-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)propionyl chloride 
• 1083099-35-7 (R)-1-(4-((2-methyloxiran-2-yl)-methoxy)phenyl)-4-(4-(trifluoro-methoxy)phenoxy)piperidine 

Relevant articles and documents

METHOD FOR PRODUCING 1-(4-HYDROXYPHENYL)-4-(4-TRIFLUOROMETHOXYPHENOXY)PIPERIDINE OR SALT THEREOF

The present invention provides a method for producing 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or a salt thereof, the method including the step of heating hydroquinone and 4-(4-trifluoromethoxyphenoxy)piperidine. This method can produce 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or a salt thereof in an industrially advantageous manner.

Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity

A series of pyrazolo[1,5-a]pyridine-3-carboxamide hybrids were designed and evaluated as novel anti-tubercular agents. The representative hybrid 7 exhibited promising in?vitro activity against susceptive strain H37Rv and a panel of drug-resistant Mtb strains with MIC values of 0.006?μg/mL and ranged from 0.003 to 0.014?μg/mL, respectively. More importantly, the hybrid 7 also showed very low cytotoxicity, and could significantly reduce the mycobacterial burden in a mouse model infected with autoluminescent H37Ra strain, which may serve as a lead compound for further development of new anti-tubercular agents.

(6,7-DIHYDRO-2-NITRO-5H-IMIDAZOL[2,1-B][1,3]OXAZIN-6YL) AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF

(6,7-Dihydro-2-nitro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)amide compounds of formula (I), and their pharmaceutically acceptable salts, preparation methods and pharmaceutical compositions thereof are disclosed, wherein m and R are defined as in the descriptio